Published online before print May 20, 2004, doi: 10.1161/01.STR.0000131546.71733.f1
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
(Stroke. 2004;35:1603.)
© 2004 American Heart Association, Inc.
Original Contributions |
A Two-Year Clinical Follow-Up Study in 80 CADASIL Subjects
Progression Patterns and Implications for Clinical Trials
From the Department of Neurology, Klinikum Grosshadern, Ludwig-Maximilians-University, Munich, Germany.
Correspondence to Dr Martin Dichgans, Department of Neurology, Klinikum Grosshadern, Ludwig-Maximilians-University, Marchioninistrasse 15, D 81377 Munich, Germany. E-mail mdichgans{at}nefo.med.uni-muenchen.de
Background and Purpose— Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL) is an inherited small vessel disease causing stroke and dementia. The aim of this study was to explore the patterns of clinical progression in CADASIL, to check for prognostic variables, and to provide sample size estimates for future therapeutic trials.
Methods— Eighty CADASIL subjects (aged 45.7±9.9 years [mean+SD]) were followed prospectively during a mean period of 26.3±1.1 months. Standardized scales on disability (Rankin), activities of daily living (Barthel index), neurological outcome (National Institutes of Health Stroke Scale [NIHSS]), and cognition (structural interview for diagnosis of Alzheimer dementia and multi-infarct dementia [SIDAM] and Mattis dementia rating scale [MDRS]) were assessed at baseline and at follow-up.
Results— All but 1 individual completed the protocol. At follow-up, the cohort had deteriorated with respect to all clinical scales: Rankin scores (0.3±0.7 [mean change±SD]; P=0.001), Barthel index (–5.4±15.9; P<0.001), NIHSS scores (1.0±2.6; P=0.001), SIDAM scores (–2.1±6.4; P=0.004), and MDRS scores (–4.3+18.5; P=0.09). The spectrum ranged from marked worsening to some degree of improvement. Seventeen patients experienced a new stroke. Overall, there were 18 strokes within 173 person-years, giving an average incidence rate of stroke of 10.4 per 100 person-years (95% CI, 5.6 to 15.2). Age at baseline was found to be a predictor of clinical progression. Sample size estimates show that the number of individuals needed to include in an interventional trial (assumed duration 2 years, assumed treatment effect 40%) is 602 when using stroke occurrence as an outcome measure.
Conclusions— The clinical course of CADASIL includes periods of acute worsening, chronic progression, stabilization, and improvement. Sample size calculations emphasize the need for surrogate markers of disease progression for future interventional trials.
Key Words: CADASIL • longitudinal studies • stroke • dementia • Notch
This article has been cited by other articles:
 |
|
 |
|
  A. Viswanathan, A. Gschwendtner, J. -P. Guichard, F. Buffon, R. Cumurciuc, M. O'Sullivan, M. Holtmannspotter, C. Pachai, M. -G. Bousser, M. Dichgans, et al. Lacunar lesions are independently associated with disability and cognitive impairment in CADASIL Neurology, July 10, 2007; 69(2): 172 - 179. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Rufa, F. Guideri, M. Acampa, G. Cevenini, S. Bianchi, N. De Stefano, M. L. Stromillo, A. Federico, and M. T. Dotti Cardiac Autonomic Nervous System and Risk of Arrhythmias in Cerebral Autosomal Dominant Arteriopathy With Subcortical Infarcts and Leukoencephalopathy (CADASIL) Stroke, February 1, 2007; 38(2): 276 - 280. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Opherk, N. Peters, M. Holtmannspotter, A. Gschwendtner, B. Muller-Myhsok, and M. Dichgans Heritability of MRI Lesion Volume in CADASIL: Evidence for Genetic Modifiers Stroke, November 1, 2006; 37(11): 2684 - 2689. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Kim, E. J. Choi, C. G. Choi, G. Kim, J. H. Choi, H. W. Yoo, and J. S. Kim Characteristics of CADASIL in Korea: A novel cysteine-sparing Notch3 mutation Neurology, May 23, 2006; 66(10): 1511 - 1516. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Peters, M. Holtmannspotter, C. Opherk, A. Gschwendtner, J. Herzog, P. Samann, and M. Dichgans Brain volume changes in CADASIL: A serial MRI study in pure subcortical ischemic vascular disease Neurology, May 23, 2006; 66(10): 1517 - 1522. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L Caeiro and J M Ferro Cognitive profile in CADASIL patients J. Neurol. Neurosurg. Psychiatry, February 1, 2006; 77(2): 144 - 145. [Full Text] [PDF]
|
|
|
|
|
|
F Buffon, R Porcher, K Hernandez, A Kurtz, S Pointeau, K Vahedi, M-G Bousser, and H Chabriat Cognitive profile in CADASIL J. Neurol. Neurosurg. Psychiatry, February 1, 2006; 77(2): 175 - 180. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Holtmannspotter, N. Peters, C. Opherk, D. Martin, J. Herzog, H. Bruckmann, P. Samann, A. Gschwendtner, and M. Dichgans Diffusion Magnetic Resonance Histograms as a Surrogate Marker and Predictor of Disease Progression in CADASIL: A Two-Year Follow-Up Study Stroke, December 1, 2005; 36(12): 2559 - 2565. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Rufa, M. T. Dotti, M. Franchi, M. L. Stromillo, G. Cevenini, S. Bianchi, N. De Stefano, and A. Federico Systemic Blood Pressure Profile in Cerebral Autosomal Dominant Arteriopathy With Subcortical Infarcts and Leukoencephalopathy Stroke, December 1, 2005; 36(12): 2554 - 2558. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Peters, C. Opherk, T. Bergmann, M. Castro, J. Herzog, and M. Dichgans Spectrum of Mutations in Biopsy-Proven CADASIL: Implications for Diagnostic Strategies Arch Neurol, July 1, 2005; 62(7): 1091 - 1094. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. J. Alberts and E. Tournier-Lasserve Update on the Genetics of Stroke and Cerebrovascular Disease 2004 Stroke, February 1, 2005; 36(2): 179 - 181. [Full Text] [PDF]
|
|
|
|
 |
|
 C. Opherk, N. Peters, J. Herzog, R. Luedtke, and M. Dichgans Long-term prognosis and causes of death in CADASIL: a retrospective study in 411 patients Brain, November 1, 2004; 127(11): 2533 - 2539. [Abstract] [Full Text] [PDF]
|
|